217 related articles for article (PubMed ID: 32198939)
1. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Catlett IM; Nowak M; Kundu S; Zheng N; Liu A; He B; Girgis IG; Grasela DM
Br J Clin Pharmacol; 2020 Sep; 86(9):1849-1859. PubMed ID: 32198939
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK).
Watterson SH; Liu Q; Beaudoin Bertrand M; Batt DG; Li L; Pattoli MA; Skala S; Cheng L; Obermeier MT; Moore R; Yang Z; Vickery R; Elzinga PA; Discenza L; D'Arienzo C; Gillooly KM; Taylor TL; Pulicicchio C; Zhang Y; Heimrich E; McIntyre KW; Ruan Q; Westhouse RA; Catlett IM; Zheng N; Chaudhry C; Dai J; Galella MA; Tebben AJ; Pokross M; Li J; Zhao R; Smith D; Rampulla R; Allentoff A; Wallace MA; Mathur A; Salter-Cid L; Macor JE; Carter PH; Fura A; Burke JR; Tino JA
J Med Chem; 2019 Apr; 62(7):3228-3250. PubMed ID: 30893553
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Smith PF; Krishnarajah J; Nunn PA; Hill RJ; Karr D; Tam D; Masjedizadeh M; Funk JO; Gourlay SG
Br J Clin Pharmacol; 2017 Nov; 83(11):2367-2376. PubMed ID: 28636208
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Leu JH; Miao X; Shalayda K; Coe KJ; Kahnt A; Wu B; Schnarr M; Franks C; Devlin J; Yang TY; Palmer JA; Zhang M; Zhou H; Van Damme W; Smets S; Aguilar Z; Chaplan SR
Clin Pharmacol Drug Dev; 2023 Jun; 12(6):611-624. PubMed ID: 37125450
[TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.
Lee SK; Xing J; Catlett IM; Adamczyk R; Griffies A; Liu A; Murthy B; Nowak M
Eur J Clin Pharmacol; 2017 Jun; 73(6):689-698. PubMed ID: 28265691
[TBL] [Abstract][Full Text] [Related]
8. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
Kaul M; End P; Cabanski M; Schuhler C; Jakab A; Kistowska M; Kinhikar A; Maiolica A; Sinn A; Fuhr R; Cenni B
Clin Transl Sci; 2021 Sep; 14(5):1756-1768. PubMed ID: 33834628
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Esfandiari E; Chen M; Smithson G; Blair D; Faessel H; Wagner J; Mclean L; Fedyk ER
Clin Transl Sci; 2021 May; 14(3):820-828. PubMed ID: 33650758
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Litzenburger T; Steffgen J; Benediktus E; Müller F; Schultz A; Klein E; Ramanujam M; Harcken C; Gupta A; Wu J; Wiebe S; Li X; Flack M; Padula SJ; Visvanathan S; Hünnemeyer A; Hui J
Br J Clin Pharmacol; 2021 Apr; 87(4):1824-1838. PubMed ID: 32986868
[TBL] [Abstract][Full Text] [Related]
11. First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants.
Merali S; Wang Z; Frost C; Meadows-Shropshire S; Hawthorne D; Yang J; Seiffert D
Platelets; 2023 Dec; 34(1):2222846. PubMed ID: 37394920
[TBL] [Abstract][Full Text] [Related]
12. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study.
Singh RSP; Pradhan V; Roberts ES; Scaramozza M; Kieras E; Gale JD; Peeva E; Vincent MS; Banerjee A; Fensome A; Dowty ME; Winkle P; Tehlirian C
Clin Transl Sci; 2021 Mar; 14(2):671-682. PubMed ID: 33290616
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).
Owens TD; Smith PF; Redfern A; Xing Y; Shu J; Karr DE; Hartmann S; Francesco MR; Langrish CL; Nunn PA; Gourlay SG
Clin Transl Sci; 2022 Feb; 15(2):442-450. PubMed ID: 34724345
[TBL] [Abstract][Full Text] [Related]
14. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Tam CS; Ou YC; Trotman J; Opat S
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
[No Abstract] [Full Text] [Related]
17. Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS.
Zheng N; Catlett IM; Taylor K; Gu H; Pattoli MA; Neely RJ; Li W; Allentoff A; Yuan X; Ciccimaro E; Yao M; Warrack BM; Burke JR; Zhang YJ; Pillutla R; Zeng J
Anal Chem; 2019 Jul; 91(13):8443-8452. PubMed ID: 31247719
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study.
Chen M; Du S; Cheng Y; Zhu X; Wang Y; Shu S; Men Y; He M; Wang H; He Z; Cai L; Zhu J; Wu Z; Li Y; Feng P
Int Immunopharmacol; 2024 Jan; 126():111285. PubMed ID: 38061118
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects.
Zhu L; Shi R; Zhao T; Ye Y; Tang J; Hu Y; Peng P; Wang D; Chong C; Xu G; Leung SO; Yuan W
Clin Transl Sci; 2023 Oct; 16(10):1982-1996. PubMed ID: 37551782
[TBL] [Abstract][Full Text] [Related]
20. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
